Abstract
Detection of biomarkers indicating disease development is critically important for the early detection of disease, particularly in complex diseases such as cancer where early detection may determine the treatment protocol and outcome. Monoclonal antibodies have been routinely used in protein detection and several biomarker discovery platforms are built using antibodies as capture and detection reagents. However, several limitations with antibodies have led to the search for new reagents. Oligonucleotide-based reagents, called aptamers, are emerging as promising alternatives to antibodies. Aptamers show several advantages over antibodies, and several aptamer-based biomarker discovery applications are increasingly being reported. In this paper, we discuss the recent developments in aptamer technology and its application in biomarker discovery.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
